CRP and neoplasm: As measurements of the levels of SCC-Ag and CRP can be performed quickly, inexpensively and repeatably in a clinical setting, we believe that the levels of SCC-Ag and CRP, as well as the combination of these two factors, could serve as relevant biomarkers of tumor aggressiveness prior to treatment in patients with PLC.